Pharmafile Logo

Relypsa

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

- PMLiVE

Vifor wins European approval for Veltassa

European Commission approves the drug to treat hyperkalaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links